Off-Label Promotion: FDA Commissioner's Concerns Stem From Ethics Of Informed Consent
This article was originally published in The Pink Sheet Daily
Executive Summary
'My personal view is that companies controlling that information is not the ideal,' Robert Califf tells BIO. 'That doesn’t mean I’ll carry the day.'
You may also be interested in...
Opioids, Abortion, And Drug Advertising: How A Califf-Led FDA Might Address Hot Button Rx Topics
Robert Califf offers some interesting clues as to how he’d handle top drug policy issues in his Senate confirmation hearing.
US FDA Pursuing Two-Track Approach To Regulatory Convergence For Cell and Gene Therapies
Discussions through the WHO are aimed at educating low- and middle-income countries, while efforts with ‘the larger regulators’ aim to reduce the development burden for products targeting ultra-rare diseases, CBER director Peter Marks tell DIA.
Peter Marks On How He Wants To Prepare For The Next Pandemic
Acknowledging the toll that vaccine opponents have taken on FDA operations, the CBER director emphasizes the need to create stand-by manufacturing capacity, conduct faster studies in special populations, and better understand the mRNA platform.